Latest News for: arve

Edit

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for ...

Nasdaq Globe Newswire 21 Apr 2025
Company to highlight preclinical study of ARV-393, an ...
Edit

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American

Hastings Tribune 21 Apr 2025
... new preclinical combination data for ARV-393 will .
Edit

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating

Hastings Tribune 04 Apr 2025
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – ... .
Edit

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central ...

Nasdaq Globe Newswire 04 Apr 2025
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers – ... .
Edit

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation (Form 8-K) (Arvinas Inc)

Public Technologies 04 Apr 2025
) Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation ... The SAD cohort evaluated ARV-102 doses ranging from 10 mg to 200 mg.
  • 1

Article Search

tools
×
×
×
×